On August 1, at the 2025 CMC-CHINA, the 7th China Pharmaceutical Industry Expo, which opened grandly in Suzhou, the industry's highly anticipated "2025 China Pharmaceutical Industry TOP 101" and 10 core industrial chain rankings were officially unveiled. Backed by its deep expertise in specialty APIs, excellent production technology and significant market influence, Newland successfully earned the title of "2025 China Specialty APIs TOP 20"!

The "2025 China Pharmaceutical Industry TOP 101" and the 10 core industrial chain rankings were jointly released by the China Pharmaceutical Industry Expo and YaoRongQuan, a renowned industry platform. Based on a rigorous multi-dimensional evaluation of massive core business revenue data, overall corporate strength and industry influence, the rankings recognize leading benchmark enterprises across various segments and carry high industry credibility.

Newland pharmaceutical inclusion in the "Specialty APIs TOP 20" list is a strong endorsement by authoritative industry bodies of the company's long-term dedication to the specialty API field. It confirms that Newland leads the industry in technology R&D, product quality, production scale and market position, and has become one of the core forces in China's specialty API sector.

For years, Newland Pharmaceutical has focused on the R&D and production of specialty APIs, committed to a development strategy driven by the twin engines of "technology and quality". Through sustained innovation, the company has built an advanced specialty API technology platform, established a complete and efficient production system, and strictly followed leading international and domestic quality management systems, ensuring excellent product quality and stable supply while providing critical raw material support to numerous pharmaceutical companies at home and abroad.

Looking ahead, Newland Pharmaceutical will take this recognition as a new starting point, continuing to increase R&D investment, optimize production processes and strengthen core competitiveness. We will deepen strategic cooperation with upstream and downstream partners, expand production capacity, actively grow in international markets and consolidate our leading position in specialty APIs. All Newland Pharmaceutical employees will remain true to the vision of "building a first-class domestic and world-advanced biomedical enterprise", pursuing excellence with determination — contributing Newland's strength to global health care and injecting new momentum into the high-quality development of China's pharmaceutical industry.